LifeStance Health Group (NASDAQ:LFST - Get Free Report) is scheduled to be posting its quarterly earnings results before the market opens on Thursday, May 9th. Analysts expect LifeStance Health Group to post earnings of ($0.09) per share for the quarter. LifeStance Health Group has set its FY 2024 guidance at EPS and its Q1 2024 guidance at EPS.Individual that are interested in participating in the company's earnings conference call can do so using this link.
LifeStance Health Group (NASDAQ:LFST - Get Free Report) last announced its quarterly earnings results on Wednesday, February 28th. The company reported ($0.12) EPS for the quarter, missing the consensus estimate of ($0.09) by ($0.03). LifeStance Health Group had a negative return on equity of 12.66% and a negative net margin of 17.64%. The firm had revenue of $280.60 million for the quarter, compared to analysts' expectations of $263.14 million. On average, analysts expect LifeStance Health Group to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.
LifeStance Health Group Price Performance
LFST stock traded up $0.08 on Thursday, reaching $6.53. The company had a trading volume of 771,707 shares, compared to its average volume of 1,275,892. LifeStance Health Group has a 1 year low of $4.74 and a 1 year high of $9.59. The company has a debt-to-equity ratio of 0.20, a quick ratio of 1.11 and a current ratio of 1.11. The company's fifty day moving average is $6.42 and its 200 day moving average is $6.53. The company has a market cap of $2.50 billion, a P/E ratio of -12.57 and a beta of 1.29.
Insider Buying and Selling at LifeStance Health Group
In related news, insider Danish J. Qureshi sold 12,965 shares of LifeStance Health Group stock in a transaction dated Monday, April 1st. The shares were sold at an average price of $5.93, for a total transaction of $76,882.45. Following the completion of the sale, the insider now owns 4,911,050 shares of the company's stock, valued at approximately $29,122,526.50. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. In other news, insider Kevin Michael Mullins sold 115,136 shares of the stock in a transaction dated Friday, March 1st. The shares were sold at an average price of $8.02, for a total value of $923,390.72. Following the completion of the sale, the insider now owns 4,575,480 shares in the company, valued at $36,695,349.60. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Danish J. Qureshi sold 12,965 shares of the firm's stock in a transaction dated Monday, April 1st. The stock was sold at an average price of $5.93, for a total transaction of $76,882.45. Following the sale, the insider now owns 4,911,050 shares of the company's stock, valued at approximately $29,122,526.50. The disclosure for this sale can be found here. In the last three months, insiders have sold 245,463 shares of company stock worth $1,786,868. Insiders own 8.50% of the company's stock.
Wall Street Analysts Forecast Growth
Several equities analysts have recently commented on the stock. Barclays increased their price target on shares of LifeStance Health Group from $7.00 to $8.00 and gave the stock an "underweight" rating in a research report on Thursday, February 29th. Jefferies Financial Group raised their target price on shares of LifeStance Health Group from $8.00 to $9.00 and gave the stock a "buy" rating in a report on Wednesday, March 6th. Morgan Stanley reaffirmed an "overweight" rating and issued a $10.00 price objective on shares of LifeStance Health Group in a research note on Monday, April 22nd. Finally, The Goldman Sachs Group lifted their target price on shares of LifeStance Health Group from $8.00 to $9.00 and gave the stock a "neutral" rating in a report on Monday, March 4th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and two have issued a buy rating to the company's stock. Based on data from MarketBeat, the company currently has an average rating of "Hold" and an average target price of $8.83.
View Our Latest Research Report on LifeStance Health Group
About LifeStance Health Group
(
Get Free Report)
LifeStance Health Group, Inc, through its subsidiaries, provides outpatient mental health services to children, adolescents, adults, and geriatrics in the United States. The company offers patients a suite of mental health services, including psychiatric evaluations and treatment, psychological, and neuropsychological testing, as well as individual, family, and group therapy.
Further Reading
Before you consider LifeStance Health Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and LifeStance Health Group wasn't on the list.
While LifeStance Health Group currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.
Get This Free Report
